EMA Backs First Combined Flu-COVID mRNA Vaccine After FDA Declines Review

What Is the First Combined Flu-COVID mRNA Vaccine?

The European Medicines Agency has recommended authorization of the first combination mRNA vaccine targeting both influenza and SARS-CoV-2. This represents a significant advance in vaccine technology, combining protection against two major respiratory pathogens into one shot. The approach builds on the mRNA platform that proved its effectiveness during the COVID-19 pandemic, now expanded to address seasonal influenza simultaneously.

Combination respiratory vaccines have been a long-sought goal in public health. Seasonal influenza and COVID-19 together contribute to hundreds of thousands of hospitalizations annually across Europe and the United States. A single-shot approach could simplify vaccination campaigns, reduce clinic visits, and potentially improve uptake rates among populations that might otherwise skip one or both vaccines. The mRNA platform allows relatively rapid updates to match circulating viral strains, a key advantage for both influenza and evolving SARS-CoV-2 variants.

Why Did the FDA Decline Review While EMA Approved It?

The contrasting decisions from the two major regulatory bodies underscore the different frameworks through which the FDA and EMA evaluate new vaccines. The FDA reportedly declined to file the application for review, which typically indicates the agency determined the submission did not meet its requirements for a complete review package. This does not necessarily reflect a safety concern but rather a procedural or data sufficiency determination. The specific reasons for the FDA's decision have not been fully disclosed publicly.

The EMA's Committee for Medicinal Products for Human Use evaluated the available clinical trial data and concluded the vaccine met European standards for efficacy, safety, and quality. Regulatory divergence between the FDA and EMA is not unprecedented — the agencies have previously reached different conclusions on vaccines and therapeutics based on their respective evidentiary thresholds. For patients and clinicians in Europe, the positive opinion means the vaccine could become available pending European Commission final authorization, which typically follows EMA recommendations.

What Does This Mean for Future Respiratory Vaccine Development?

The authorization of a combined flu-COVID mRNA vaccine in Europe sets a precedent for the broader respiratory vaccine field. Several pharmaceutical companies are developing combination vaccines that target influenza, COVID-19, and potentially respiratory syncytial virus in a single formulation. The mRNA platform's modularity — the ability to encode antigens from multiple pathogens in one construct — makes it particularly suited for such combination approaches. According to the World Health Organization, influenza alone causes an estimated 290,000 to 650,000 respiratory deaths globally each year, underscoring the public health value of streamlined vaccination strategies.

For healthcare systems, a single combination vaccine could reduce logistical complexity during autumn vaccination campaigns. Current guidance in many countries recommends separate influenza and COVID-19 vaccinations, often requiring two appointments or simultaneous injections in different arms. A proven combination product could improve compliance, particularly among older adults and immunocompromised populations who are most vulnerable to both infections. The regulatory pathway established by this EMA decision will likely inform how future combination mRNA vaccines are evaluated worldwide.